Division of Pulmonary and Critical Care Medicine, University of North Carolina, School of Medicine, Chapel Hill, NC, USA.
Verona Pharma plc, Raleigh, NC, USA.
Int J Chron Obstruct Pulmon Dis. 2023 Jul 28;18:1611-1622. doi: 10.2147/COPD.S413436. eCollection 2023.
Ensifentrine is a novel, potent, and selective dual inhibitor of phosphodiesterase (PDE)3 and PDE4 designed for delivery by inhalation that combines effects on airway inflammation, bronchodilation and ciliary function in bronchial epithelia. In Phase 2 studies in subjects with COPD, ensifentrine demonstrated clinically meaningful bronchodilation and improvements in symptoms and health-related quality of life when administered alone or in combination with current standard of care therapies. Ensifentrine is currently in late-stage clinical development for the maintenance treatment of patients with COPD. This review summarizes non-clinical data as well as Phase 1 and Phase 2 efficacy and safety results of nebulized ensifentrine relevant to the maintenance treatment of patients with COPD.
依诺司林是一种新型强效、选择性磷酸二酯酶（PDE）3 和 PDE4 双重抑制剂，设计用于吸入给药，可同时作用于气道炎症、支气管扩张和支气管上皮纤毛功能。在 COPD 患者的 2 期研究中，依诺司林单独或与当前标准治疗联合应用时，可实现有临床意义的支气管扩张，并改善症状和健康相关生活质量。依诺司林目前处于 COPD 患者维持治疗的后期临床开发阶段。本综述总结了与 COPD 患者维持治疗相关的非临床数据以及雾化依诺司林的 1 期和 2 期疗效和安全性结果。
